Ann: Proposed grant of options to Directors, page-4

Turnover is pretty small. In all honesty 6 months ago it was pretty similar, except the price was 1c higher. At that time though I had been to the AGM and I had seen the presentation by Jackie and Professor Faul, and I had seen the confidence and excitement of the CEO and Bob Elliot, and I knew they knew the result of the first patient so I just vacuumed up the shares at low prices. Should have waited till now though, but who expected this price.
I have to say though that anyone selling the shares at 4.2c ahead of Diabecell getting FDA approval would probably do much better to wait a few months.